Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on November 29, 2016. The filing primarily announces the entry into a material definitive agreement to facilitate an equity offering and provides updates to business operations and risk factors.
Key Financial Metrics
The filing does not report specific revenue, profit, cash flow, or margin figures for a specific period. The primary financial metric disclosed relates to the potential capital raise:
- Maximum Offering Size: Up to $40,000,000 in aggregate offering price.
- Agent Commission: Up to 3.0% of gross proceeds from the sale of shares.
- Debt and Liquidity: The filing text does not provide specific values for current debt levels or liquidity positions.
Material Changes
The material change reported is the execution of a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on November 29, 2016. This agreement allows the company to sell shares of its common stock through an "at the market" offering. Additionally, the company filed updated risk factors and an update regarding business operations, clinical trials, and regulatory submissions, superseding previous disclosures in its 2015 Annual Report and Q3 2016 Quarterly Report.
Guidance, Outlook, and Risks
Outlook and Commentary: The company intends to utilize the Sales Agreement to raise capital from time to time. The offering can be suspended or terminated by either party upon notice. The company filed an update on its clinical trials and regulatory submissions as Exhibit 99.1.
Risks and Contingencies: The filing includes updated risk factors (Exhibit 99.2) that supersede those in prior periodic reports. The text does not detail specific unusual items or contingencies beyond the standard risks associated with equity offerings and clinical development.
Investor Verification Checklist
- Verify the current share price and the number of shares outstanding to assess potential dilution from the $40,000,000 offering.
- Review Exhibit 99.1 for specific details on the status of clinical trials and regulatory submissions.
- Examine Exhibit 99.2 for the updated risk factors that may impact the company's operational outlook.
- Confirm the company's current cash position in the most recent 10-Q or 10-K to understand the necessity of this capital raise.